🚀 VC round data is live in beta, check it out!
Estrella Immunopharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Estrella Immunopharma and similar public comparables like Prescient Therapeutics, Lipocine, SyntekaBio, NextCure and more.
Estrella Immunopharma Overview
About Estrella Immunopharma
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
Founded
2022
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$44M
Estrella Immunopharma Financials
Estrella Immunopharma reported last 12-month revenue of —.
In the same LTM period, Estrella Immunopharma generated had net loss of ($40M).
Revenue (LTM)
Estrella Immunopharma P&L
In the most recent fiscal year, Estrella Immunopharma reported revenue of — and EBITDA of ($7M).
Estrella Immunopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($7M) | XXX | XXX | XXX |
| Net Profit | ($40M) | XXX | ($7M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Estrella Immunopharma Stock Performance
Estrella Immunopharma has current market cap of $46M, and enterprise value of $44M.
Market Cap Evolution
Estrella Immunopharma's stock price is $1.09.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $44M | $46M | 0.0% | XXX | XXX | XXX | $-0.17 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEstrella Immunopharma Valuation Multiples
Estrella Immunopharma trades at (6.0x) EV/EBITDA.
Estrella Immunopharma Financial Valuation Multiples
As of March 18, 2026, Estrella Immunopharma has market cap of $46M and EV of $44M.
Equity research analysts estimate Estrella Immunopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Estrella Immunopharma has a P/E ratio of (1.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $46M | XXX | $46M | XXX | XXX | XXX |
| EV (current) | $44M | XXX | $44M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (6.0x) | XXX | XXX | XXX |
| EV/EBIT | (1.1x) | XXX | (6.0x) | XXX | XXX | XXX |
| P/E | (1.1x) | XXX | (6.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (2.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Estrella Immunopharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Estrella Immunopharma Margins & Growth Rates
Estrella Immunopharma's revenue in the last fiscal year grew by —.
Estrella Immunopharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (21%) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Estrella Immunopharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Lipocine | XXX | XXX | XXX | XXX | XXX | XXX |
| SyntekaBio | XXX | XXX | XXX | XXX | XXX | XXX |
| NextCure | XXX | XXX | XXX | XXX | XXX | XXX |
| Intercure | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Estrella Immunopharma M&A Activity
Estrella Immunopharma acquired XXX companies to date.
Last acquisition by Estrella Immunopharma was on XXXXXXXX, XXXXX. Estrella Immunopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Estrella Immunopharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEstrella Immunopharma Investment Activity
Estrella Immunopharma invested in XXX companies to date.
Estrella Immunopharma made its latest investment on XXXXXXXX, XXXXX. Estrella Immunopharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Estrella Immunopharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Estrella Immunopharma
| When was Estrella Immunopharma founded? | Estrella Immunopharma was founded in 2022. |
| Where is Estrella Immunopharma headquartered? | Estrella Immunopharma is headquartered in United States. |
| Who is the CEO of Estrella Immunopharma? | Estrella Immunopharma's CEO is Cheng Liu. |
| Is Estrella Immunopharma publicly listed? | Yes, Estrella Immunopharma is a public company listed on Nasdaq. |
| What is the stock symbol of Estrella Immunopharma? | Estrella Immunopharma trades under ESLA ticker. |
| When did Estrella Immunopharma go public? | Estrella Immunopharma went public in 2023. |
| Who are competitors of Estrella Immunopharma? | Estrella Immunopharma main competitors are Prescient Therapeutics, Lipocine, SyntekaBio, NextCure. |
| What is the current market cap of Estrella Immunopharma? | Estrella Immunopharma's current market cap is $46M. |
| Is Estrella Immunopharma profitable? | No, Estrella Immunopharma is not profitable. |
| What is the current net income of Estrella Immunopharma? | Estrella Immunopharma's last 12 months net income is ($40M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.